First Patients Dosed in SPONTAN Phase II Clinical Study

LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that the first patients have been dosed in its Phase II pharmacokinetic clinical study of SPONTAN®, its rapid-acting intranasal spray for the treatment of erectile dysfunction. First patient dosing marks the transition of the study from recruitment into active pharmacokinetic data generation, representing a signifi